How Clinical Trials Work

A clinical trial is a research study that tests a new way to prevent, find, or treat cancer. People volunteer to take part. What is learned helps doctors care for future patients.

Trials follow a careful written plan. Doctors and nurses watch each person closely. Every trial has rules about who can join and steps to protect the people who take part.

Taking part is always your choice. You can ask questions at any time, and you can decide not to join.

Treatment trials often move through steps called phases. Each phase answers different questions and builds on what came before.

Early phases test whether a treatment is safe and how the body handles it. Later phases test how well it works and compare it with the care most people already receive.

A treatment usually moves to the next phase only after earlier studies suggest it is reasonable to keep testing.

Phase 1 trials are the first step in testing a new treatment in people. They usually include a small number of volunteers.

The main goal is safety. Researchers look at how the body handles the treatment and watch for side effects. They also try to learn a safe dose.

Phase 2 trials include more people than phase 1. They look at whether the treatment seems to work for a certain type of cancer.

Researchers keep watching for side effects during this phase. If the results look promising, the treatment may move on to a phase 3 trial.

Phase 3 trials usually include many people, often at hospitals and clinics in more than one place. They compare a new treatment with the treatment most people already receive, called standard of care.

These trials help show whether a new approach is better than, or as good as, current care. Results from phase 3 trials often help decide whether a treatment becomes widely available.

Phase 4 trials happen after a treatment has been approved and is in use. They gather more information over time.

These studies can look at long-term safety, how the treatment works in more people, and how it fits with everyday care.

Some trials compare two or more groups. To keep the comparison fair, a computer may place each person into a group by chance. This is called randomization.

Randomization helps make the groups alike so the results are more reliable. Neither you nor your doctor chooses your group. Your care team still watches over you closely no matter which group you are in.

A placebo is an inactive look-alike, sometimes called a sugar pill. Many people worry they will get a placebo instead of treatment. NCI says placebos are rarely used in cancer clinical trials.

When a proven treatment already exists, it would not be ethical to leave people untreated. So a placebo is rarely used alone in cancer treatment trials.

NCI says placebos are usually used only when no standard treatment exists, or they can be added to a standard treatment. One group may get standard care plus the new treatment, and the other gets standard care plus a placebo. Your study team will tell you if the study uses a placebo.

Standard of care is the treatment that experts agree is best for a certain cancer right now. It is the care most people would receive.

In many treatment trials, standard of care is the comparison. A new approach is tested next to it, or added on top of it, so researchers can see whether the new approach helps.

Informed consent is how you learn about a trial before deciding to join. The team explains the study's purpose, what will happen, the possible benefits, and the known risks.

You can ask questions. If you decide to join, you sign a consent form. Even after you sign it, you can leave the study at any time.

The team should keep you informed during the study too. NCI says that as new information becomes available, the research team will inform you.

Every trial has rules about who can join. These rules are called eligibility criteria. They may include the type and stage of cancer, past treatments, age, and overall health.

These rules help keep people safe and help the results make sense. Reasons to join are called inclusion criteria. Reasons a trial may not be a fit are called exclusion criteria.

Only the research team can decide whether a specific trial is a match for a specific person. This page explains the idea, not your own eligibility. Your oncology team can help you understand which trials, if any, may fit your situation.

A biomarker is something in the body, blood, or a tumor that can be measured. Doctors use biomarkers to learn more about a cancer.

Some trials use biomarkers to help decide who may join or to see how a treatment is working. Testing for a biomarker is often done from blood or a tissue sample. Your team can explain any tests a trial may involve.

Many trials include a control group. This group receives the standard treatment, or sometimes standard care plus a placebo.

The control group gives researchers something to compare the new approach against. Comparing groups helps show whether any change is really from the new treatment.

Your safety comes first in a clinical trial. The team checks on you often with visits, exams, and tests.

They watch for side effects and act if something comes up. Trials also have outside groups and written rules that add more layers of safety.

An institutional review board, or IRB, is a group that reviews a trial before it can begin. It includes doctors, scientists, and members of the community.

The IRB checks that the study is ethical and that people's rights and safety are protected. It reviews the plan and the consent form, and it keeps watching the trial over time.

Trials have rules about when a study should stop early. These are set before the trial begins.

A trial may stop early if the treatment looks clearly helpful, if it seems to cause harm, or if it is clear the study will not answer its question. These rules help protect the people who take part.

A data and safety monitoring committee is a group of experts who are not running the trial. They review the study's results while it is going on.

This group looks at safety information and can recommend changes, such as stopping a trial early if needed. It adds an extra layer of protection for the people in the study.

Rare cancers affect a small number of people, which can make them harder to study. Trials for rare cancers often bring together patients from many hospitals and even many countries.

Taking part in a trial can be one way to access research focused on a rare cancer. Your oncology team can help you learn what studies may be open.

Children can take part in clinical trials.

For a child to join, a parent gives permission. The child is also asked whether they agree to take part (called assent), in words they can understand. NCI says both parents usually need to give permission, with some exceptions.

Not all trials test treatments. Survivorship research studies life during and after cancer care.

These studies may look at long-term effects, healthy habits, and ways to help people stay well after treatment ends. What is learned can improve care for future survivors.

Supportive care trials, sometimes called symptom management trials, test ways to help people feel better. They may study ways to ease side effects like nausea, pain, or tiredness.

The goal is comfort and well-being, not a cure. These trials can run alongside cancer treatment.

Quality-of-life studies look at how cancer and its care affect daily life. They may ask about physical comfort, emotions, and how people manage day to day.

These studies help teams understand what matters most to patients. That understanding can shape kinder, more complete care.